



Cochrane

Kidney and Transplant

Study name: 2VAL 2010 Kidney

Register status: Accepted

Status of study: Closed

Contact details:

Study acronym & full name 2VAL: Two Valine Esters Study

Date entered: 4/07/2011

Date edited: 26/02/2018

Date to Central: 8/08/2011

Study Registration ACTRN12610000016033; CRG090700119

URL to Study Registration <http://www.anzctr.org.au/ACTRN12610000016033.aspx>

Study notes:

DESIGN

RCT

INCLUDED IN REVIEWS

Hodson CRG002, Elisabeth

REVIEW TITLE

Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients

SECTION

Included

INTERVENTIONS

Valacyclovir

Valganciclovir

HEALTH CARE CONDITIONS

Cytomegalovirus (CMV)

Kidney Transplantation

REFERENCES

- Kacer M, Kielberger L, Bouda M, Reischig T. Pharmacoeconomic impact of valganciclovir versus valacyclovir for cytomegalovirus prophylaxis in renal transplant recipients: A randomized controlled trial [abstract]. Transplantation. 2014; 98(Suppl 1) : 763.
- Kacer M, Kielberger L, Bouda M, Reischig T. Valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus: an economic perspective. Transplant Infectious Disease. 2015; 17(3) : 334-341.
- Reischig T, Jindra P, Hes O, Lysak D, Bouda M. Randomized comparison of valganciclovir and valacyclovir for cytomegalovirus prophylaxis [abstract no:O026]. Transplant International. 2013; 26(Suppl 2) : 29.

- Reischig T, Jindra P, Hes O, Lysak D, Bouda M. The 2VAL study: Randomized comparison of valganciclovir vs. valacyclovir for cytomegalovirus prophylaxis after renal transplantation [abstract]. *Transplantation*. 2012; 94() : 541.
- Reischig T, Jindra P, Hes O, Lysak D, Bouda M. The 2VAL Study: Randomized comparison of valganciclovir vs. valacyclovir for cytomegalovirus prophylaxis after renal transplantation [abstract no: LB19]. *American Journal of Transplantation*. 2012; 12(Suppl S3) : 361.
- Reischig T, Kacer M, Hrubá P, Hermanová H, Hes O, Lysak D, Kormunda S, Bouda M. Less renal allograft fibrosis with valganciclovir prophylaxis for cytomegalovirus compared to high-dose valacyclovir: a parallel group, open-label, randomized controlled trial. *BMC Infectious Diseases*. 2018 Nov 15; 18(1) : 573.
- Reischig T, Kacer M, Hrubá P, Lysak D, Jindra P, Hes O, Bouda M. Long-term outcomes of valganciclovir versus valacyclovir for cytomegalovirus prophylaxis in renal transplantation: a parallel group, open-label randomized controlled trial. [abstract no:SA-PO482]. *Journal of the American Society of Nephrology*. 2017; 28(Abstract Suppl)
- Reischig T, Kacer M, Jindra P, Hes O, Lysak D, Bouda M. Randomized trial of valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation. *Clinical Journal of the American Society of Nephrology: CJASN*. 2015;
- Reischig T, Prucha M, Sedlacková L, Jindra P, Bouda M, Matejovic M. Lymphocyte function during valacyclovir and valganciclovir cytomegalovirus prophylaxis in renal transplant recipients [abstract no: 349]. *American Journal of Transplantation*. 2010; 10(Suppl 4) : 143.
- Reischig T, Prucha M, Sedlacková L, Lysak D, Bouda M, Matejovic M. Valganciclovir prophylaxis against cytomegalovirus impairs lymphocyte proliferation and activation in renal transplant recipients. *Antiviral Therapy*. 2011; 16(8) : 1227-35.